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Summary
Systemic therapy of metastatic breast cancer is not curative and its goal is life prolongation and improvement of qual-
ity of life. Treatment of metastatic breast cancer usually involvesendocrine therapy and/or chemotherapy with or without 
targeted therapy. The use of the minimally toxic endocrine therapies is preff ered to the use of cytotoxic therapy whenever 
reasonable.
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SUSTAVNO ANTINEOPLASTIČNO LIJEČENJE METASTATSKOG RAKA DOJKE
Sažetak
Sustavno liječenje metastatskog raka dojke nije kurativno već se provodi u svrhu produženja života i poboljšanja kva-
litete života. Sustavno liječenje se sastoji od endokrine terapije i/ili kemoterapije uz ili bez primjene ciljane biološke terapije. 
U liječenju metastatskog raka dojke preferirani oblici liječenja su oni najmanje toksični te se endokrina terapija primjenjuje 
kad god je to moguće.
KLJUČNE RIJEČI: karcinom dojke, hormonska terapija, citotoksični lijekovi, biološka terapija, bisfosfonati
Metastatic breast cance r is an incurable dis-
ease so the goal of treatment is to prolong patients’ 
life and improve its quality. Depending on a num-
ber of factors, such as immunohistological type of 
disease, location of metastases, patients’ condition 
and previous treatment, diff erent types of therapy 
listed hereafter could be used.
I. Endocrine therapy
Endocrine therapy sho uld generally be con-
sidered as initial treatment for a breast cancer pa-
tient with metastatic disease: if the patient’s tumor 
is estrogen receptor (ER)-positive, progesterone 
receptor (PR)-positive, or ER/PR-unknown; if the 
patients disease involves only bones and soft tis-
sue and if the patient either received no adjuvant 
antiestrogen therapy or if such therapy has not 
been applied for more than 1 year (1). Patients 
with lymphangitic pulmonary metastases, major 
liver involvement and/or central nervous system 
involvement should not receive endocrine thera-
py as a single treatment modality. Early failure 
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(e.g.<6 months) ofendocrine therapy suggests that 
cytotoxic chemotherapy should be used as the 
next modality of treatment. Some premenopausal 
women should undergo oophorectomy (surgical-
ly, with external-beam radiation therapy or with a 
LHRH agonist) (2).Endocrine therapy may be also 
active in patients with negative ER and PR recep-
tors, especially on primary tumor and in softt issue 
disease and/or bone-dominant disease (3-5).
In premenopausal women, endocrine thera-
pies include selective estrogen receptor modula-
tors (SERMs) (tamoxifen or toremifene), luteiniz-
ing hormone-releasing hormone (LHRH) agonists 
(goserelin and leuprolide), surgical or radiothera-
peutic oophorectomy, progestin (megestrol ace-
tate), androgens (fl uoxymesterone), and high-
dose estrogen (ethinylestradiol). For most pre-
menopausal patients, following therapy with 
tamoxifen, the use of ovarian suppression or abla-
tion in combination with endocrine therapy for 
postmenopausal women is appropriate.
First-line endocrine therapy in postmeno-
pausal women includesaromatase inhibitors (AI): 
nonsteroidalaromatase inhibitors (anastrozole, 
 letrozole) andsteroidal aromatase inhibitors (exe-
mestane), selective ER modulators (tamoxifen, 
 toremifene), ER down regulators (fulvestrant), 
progestin (megestrol acetate), androgens (fl uo-
xymesterone), and high-dose estrogens (ethinyl-
estradiol) and some new recently approved com-
binations. While tamoxifen has been used in this 
sett ing for many years, several randomized trials 
suggest equivalent or superior response rate (RR) 
and progression free survival (PFS) for the AIs 
compared to tamoxifenas well as bett er tolerabili-
ty (less thromboembolic events and vaginal bleed-
ing). In comparison to megestrol acetate, all three 
currently available aromatase inhibitors have 
demonstrated, in prospective randomized trials, 
at least equal effi  cacy and bett er tolerability (10-
20). In a meta-analysis that included randomized 
trials in patients who were receiving an AI as ei-
ther their fi rst or second line ofendocrine therapy 
for metastatic disease, those who were randomly 
assigned to a selective AI lived longer (HR for 
death, 0.87; 95% CI, 0.82–0.93) than those who re-
ceived standard therapy (tamoxifen or a progesta-
tional agent) (21). Several randomized bu t under-
powered trials have tried to determine if com-
bined endocrine therapy (LHRH agonists plusta-
moxifen) is superior to any monotherapy in pre-
menopausal women. Results have been inconsis-
tent (22-25). Two randomized trials t hat enrolled 
patients who had progressed after receiving 
tamoxifen demonstrated that fulvestrant yielded 
similar results to anastrozole in terms of its impact 
on PFS (26,27). The updated follow-up results 
showed an improved time to progression (TTP) 
with fulvestrant 500 mg compared to anastrozole 
(median TTP 23.4 months for fulvestrant vs. 13.1 
months for anastrozole; HR, 0.63; 95% CI, 0.39–
1.00; P=0.0496). Fulvestrant appears to be at least 
as eff ective as anastrozole in patients whose dis-
ease progressed on previous tamoxifen, and a re-
analysis of these studies suggested a longer dura-
tion of response favoring fulvestrant (28). The 
proper sequencing of these therapies is currently 
not known (29). Phase III randomized study 
(CONFIRM) compared fulvestrant 500 mg month-
ly versus fulvestrant 250 mg monthly. The PFS 
was superior with the fulvestrant 500 mg regimen 
(HR 0.80; 95% CI, 0.68–0.94; P= .006) and the fi nal 
analyses demonstrated an increase in median OS 
(4.1 months) and reduced risk of death (19%) with 
a dose of 500 mg compared to 250 mg. Median OS 
was 26.4 vs. 22.3 months (HR: 0.81; 95% CI: 0.69-
0.96; P= .016) (30). Two studies documented a PFS 
advantage when adding trastuzumabto anastro-
zole (TANDEM study) or lapatinib to letrozole in 
postmenopausal women with HR-positive, HER2-
positive metastatic breast cancer. Overall survival 
showed no statistically signifi cant diff erence and 
adverse eff ects (AEs) were more frequent with the 
combination (31,32).
However, patients inevitably develop resis-
tance to endocrine therapy. The clinical benefi t 
rates of exemestane and fulvestrant observed in a 
phase III trial of postmenopausal women with 
HR-positive advanced breast cancer who experi-
enced disease progression on prior non-steroidal 
AI therapy were comparable (32.2% vs. 31.5%; 
P = 0.853) (33).While there is a biologic rationale 
for combining fulvestrant with a third-generation 
aromatase inhibitor for patients with non-steroi-
dal AI resistant disease, the benefi ts of such com-
bination therapy have not been established 
(SoFEA trial) (34). One mechanism of resist ance to 
endocrine therapy is activation of the mammalian 
target of rapamycin (mTOR) signal transduction 
pathway. BOLERO-2is a randomized , phase III 
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trial, of randomly assigned patients with HR-po-
sitive metastatic breast cancer resistant to non-ste-
roidal AI who received the mTOR inhibitor eve-
rolimus plus exemestane versus placebo plus ex-
emestane. Median PFS was 6.9 months for eve-
rolimus plus exemestane and 2.8 months for pla-
cebo plus exemestane (HR, 0.43; 95% CI, 0.35–0.54; 
P< .001). Final OS outcomes are awaited. The addi-
tion of everolimus was found to be more toxic 
with common grade 3 or 4 AE which included sto-
matitis, anemia, dyspnea, hyperglycemia, fatigue, 
and pneumonitis (35).
After second-line endocrine therapy, litt le 
high-level evidence exists to assist in selecting the 
optimal sequence of endocrine therapy.
II. Cytotoxic chemotherapy
Candidates for cytotoxic chemotherapy are 
patients with hormone receptor–negative tumors, 
those with visceral metastases andpatients whose 
tumors have progressed on endocrine therapy 
(36). Single agents that have shown activity in 
metastatic breast cancer are:
Anthracyclines: doxorubicin, epirubicin, li-
posomal doxorubicin (37-40), mitomycin.
Microtubuleinhibitors: taxanes [paclitaxel 
(41,42), nanoparticle albumin-boundpaclitaxel 
(43,44), docetaxel], vinca alkaloids [vinorelbine 
(45), vinblastine], eribulin (46,47).
Alkylating agents: cyclophosphamide, car-
boplatin, cisplatin.
Antimetabolites: fl uoropyrimidines [5-FU 
and capecitabine (48-50)], gemcitabine (51).
Combination regimens that have shown ac-
tivity in metastatic breast cancer are:
Cyclophosphamide/doxorubicin (52), epiru-
bicin/doxorubicin (53), cyclophosphamide/doxo-
rubicin/5-fl uorouracil (54), cyclophosphamide/epi-
rubicin/5-fl uorouracil (55), cyclophosphamide/
methotrexate/5-fl uorouracil (56), docetaxel/doxo-
rubicin (57), paclitaxel/doxorubicin (58,59), do-
cetaxel/capecitabine (60), vinorelbine/epirubicin 
(61), capecitabine/ixabepilone (62), gemcitabine/
paclitaksel (63), gemcitabine/carboplatin (64).
It is unclear which of single-agent chemo-
therapy or combination chemotherapy is prefera-
ble for fi rst-line treatment. An Eastern Coopera-
tive Oncology Intergroup study randomly as-
signed patients to receive paclitaxel and doxo-
rubicin given both as a combination and sequen-
tially (65). Although RR and TTP were both bett er 
for the combination, OS was the same in both 
groups (66-68). Considering that there is no data 
on supporting the superiority of any particular 
regimen.The rate of disease progression, comor-
bid medical conditions, and physician/patient 
preference will infl uence the choice of therapy in 
individual patients.
Combinations of chemotherapy and endo-
crine therapy have not shown an OS advantage 
over the sequential use of these agents (1,69). The 
addition of one or more chemotherapy drugs to a 
chemotherapy regimen in the att empt to intensify 
the treatment improved RR but had no eff ect on 
OS (70). The optimal treatment duration for pa-
tients with responsive disease has been studied by 
several groups.Studies indicate that additional 
chemotherapy, immediately following patients 
best response to an induction chemotherapy regi-
men, does not improve OS (71-73).
Studies comparing high-dose (HD) chemo-
therapy with stem cell support to conventional 
chemotherapy in patients with metastatic disease 
indicate no OS orrelaps free survival (RFS) benefi t 
for patients receiving HD chemotherapy (74-77).
The potential doxorubicin-induced cardiac toxic 
eff ects should be considered in the selection of 
chemotherapeutic regimens for an individual pa-
tient. Recognized risk factors for cardiac toxicity 
include advanced age, prior chest-wall radiation 
therapy, prior anthracycline exposure, hyperten-
sion, diabetes, and known underlying heart dis-
ease.
The cardioprotective drug, dexrazoxane, has 
been shown to decrease the risk of doxorubicin-
induced cardiac toxicity, it permitt ed patients to 
receive greater cumulative doses of doxorubicin 
and allowed patients with cardiac risk factors to 
receive doxorubicin. Dexrazoxane has a similar 
protective eff ect in patients receiving epirubicin.
The risks of cardiac toxicity may be reduced by 
administering doxorubicin as a continuous intra-
venous infusion (78-83).
III. Targeted therapy
T argeted therapies are drugs that block the 
growth and spread of cancer by interfering with 
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specifi c molecules involved in tumor growth and 
progression. There are two main types of targeted 
therapy drugs which can be used in breast cancer:
Monoclonal antibodies: trastuzumab, beva-
cizumab, pertuzumab.
Small molecules (tyrosine-kinase inhibi-
tors): lapatinib.
Trastuzumab - approximately 20% of  patients 
with breast cancer have tumors that overexpress 
HER2/neu protein. Trastuzumab is a humanized 
monoclonal antibody that binds to the HER2 re-
ceptor (84). In patients previously treated with cy-
totoxic chemotherapy whose tumors overexpress 
HER2/neu protein, administration of trastuzumab 
as a single agent resulted in a response rate of 21% 
(85). In a prospective trial, patients with metastatic 
disease were randomly assigned to receive either 
chemotherapy alone (doxorubicin and cyclophos-
phamide or paclitaxel) or the same chemotherapy 
and trastuzumab. Patients treated with chemo-
therapy plus trastuzumab had an OS advantage 
compared to those receiving chemotherapy alone 
(25.1 months vs. 20.3 months, P=0.05) (86). When 
combined with doxorubicin, trastuzumab is asso-
ciated with signifi cant cardiac toxicity (87). Conse-
quently, patients with metastatic breast cancer 
with substantial overexpression of HER2/neupro-
tein are candidates for treatment with the combi-
nation of trastuzumab and paclitaxel or for clinical 
studies includingtrastuzumab combined with tax-
anes and other chemotherapeutic agents (88). 
Clinical trials that co mparedmultiagent chemo-
therapy plus trastuzumabto single-agent chemo-
therapy have yielded confl icting results (89,90). 
Outside of a clinical trial, standard fi rst-line treat-
ment for metastatic HER2-overexpressing breast 
cancer should consist of single-agent chemothera-
py plus trastuzumab.
Ado-TrastuzumabEmtansine(T-DM1) - is 
an antibody-drug conjugate that incorporates the 
HER2–targeted antitumor properties of trastu-
zumab with the cytotoxic activity of the microtu-
bule-inhibitory agent DM1. T-DM1 allows specifi c 
intracellular drug delivery to HER2-overexpress-
ing cells, potentially improving the therapeutic 
index and minimizing exposure of normal tissue. 
The phase III randomized study (EMILIA) en-
rolled 991 patients with HER2-overexpressing, 
unresectable, locally advanced or metastatic breast 
cancer who were previously treated with trastu-
zumab and a taxane (91).Patients were randomly 
assigned to T-DM1 orlapatinib plus capecitabine. 
Median PFS was 9.6 months with T-DM1 versus 
6.4 months with lapatinib plus capecitabine (HR, 
0.65; 95% CI, 0.55–0.77; P<0.001). Median OS 
crossed the stopping boundary for effi  cacy (30.9 
months vs. 25.1 months; HR, 0.68; 95% CI, 0.55–
0.85; P<0.001). The incidences of thrombocytope-
nia and increased serum aminotransferase levels 
were higher in patients who received T-DM1, 
whereas the incidences of diarrhea, nausea, vom-
iting, and palmar–plantar syndrome were higher 
in patients who received lapatinib plus capeci-
tabine.
Pertuzumab - is a humanized, monoclonal 
antibody that binds to a diff erent epitope of the 
HER2 extracellular domain than trastuzumab 
does. The binding of pertuzumab to HER2 pre-
vents dimerization with other ligand-activated 
HER receptors, most notably HER3. The phase III 
CLEOPATRAtrial assessed the effi  cacy and safety 
of pertuzumab plus trastuzumab plus docetaxel 
versus placebo plus trastuzumab plus docetaxel, 
in the fi rst-line HER2+ metastatic sett ing (92). The 
median PFS was 12.4 months in the control group 
versus 18.5 months in the pertuzumab group (HR, 
0.62; 95% CI, 0.51–0.75; P<0.001). At the median 
follow-up of 30 months the results showed statis-
tically signifi cant improvement in OS in favour of 
pertuzumab containing regimen, with 34% reduc-
tion in the risk of death. At median follow-up of 50 
months (range 0 to 70 months), the statistically 
signifi cant improvement in OS in favour of pertu-
zumab/trastuzumab/docetaxel arm was main-
tained (HR = 0.68, P= 0.0002). Median OS was 40.8 
months in the placebo arm and 56.5 months in the 
pertuzumab arm, with diff erence of 15.7 months. 
The toxicity profi le was similar in both treatment 
groups with no increase in cardiac toxic eff ects 
seen in the pertuzumab combination arm.
Bevacizumab – is a humaniz ed monoclona l 
antibody directed against all isoforms of vascular 
endothelial growth factor-A. Its role in the treat-
ment of metastatic breast cancer remains contro-
versial. The effi  cacy and safety of bevacizumab as 
a second- and third-line treatment for patients 
with metastatic breast cancer were studied in sev-
eral randomized, phase III trials (e.g. ECOG-2100, 
AVADO, RIBBON 1, RIBBON 2) (93-97). Based on 
the consistent fi nding that bevacizumab only 
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modestly improved PFS but not OS, and given its 
considerable toxicity profi le (e.g. hypertension, 
proteinuria), the Food and Drug Administration 
(FDA) revoked approvalof bevacizumab for the 
treatment of metastatic breast cancer.
Lapatinib - is an orally administered tyrosine 
kinase inhibitor of both HER2/neu and the epider-
mal growth factor receptor.Lapatinib has shown 
activity in combination with capecitabine in pa-
tients who have HER2-positive metastatic breast 
cancer refractory to trastuzumab.A non-blinded, 
randomized trial compared the combination of 
capecitabine and lapatinib with capecitabine alone 
in 324 patients with locally advanced or metastatic 
disease that progressed to therapies that included 
anthracyclines, taxanes, and trastuzumab. Highly 
signifi cant diff erence was found that favored the 
combination arm with respect to the primary 
study endpoint and time to progression (median 
time to progression 8.4 months vs. 4.4 months; 
HR, 0.49; 95% CI, 0.34–0.71; P<0.001). There was 
no diff erence in OS (HR, 0.92; 95% CI, 0.58–1.46; 
P= 0.72) (98). Patients randomized to combination 
therapy were more likely to develop diarrhea, 
rash, and dyspepsia.
The combination of lapatinib and trastuzum-
ab has been evaluated for patients with HER2-
positive metastatic breast cancer whose disease 
progressed while they were being treated with 
trastuzumab in a phase III trial (99). A total of 291 
patients were randomly assigned to treatment 
with lapatinib alone or to combination with trastu-
zumab. Compared with lapatinib alone, the com-
bination of lapatinib and trastuzumab signifi cant-
ly improved PFS (HR, 0.74; 95% CI, 0.58–0.94; me-
dian, 11 weeks vs. 8 weeks) and OS (HR, 0.74; 95% 
CI, 0.57–0.97; median, 14 months vs. 10 months). 
The control arm, lapatinib alone is a nonstandard 
treatment arm.
These data off er heavily pretreated metastat-
ic HER2-positive breast cancer patients an alterna-
tive chemotherapy-free treatment regimen using 
dual HER2 blockade. Randomized phase III study 
compared paclitaxel and lapatinib with paclitaxel 
plus placebo as fi rst-line therapy in patients with 
metastatic breast cancer, but no benefi t was found 
with the combination treatment. Toxicities, spe-
cifi cally alopecia, diarrhea, and rash were higher 
in the HER2/neu-positive lapatinib group (100).
IV. Supportive therapy for bone metastases
The bisphosphonates and denosumab may 
be used as supportive therapy to reduce skeletal 
related events (SREs) in patients with bone metas-
tases (101). Results of randomized trials of pami-
dronate and clodronate in patients with bone me-
tastaseshave shown decreased skeletal morbidity 
(102-104). Zoledronate has been at least as eff ec-
tive as pamidronate (105). Denosumab has bett er 
activity compared to zolendronate. This is based 
upon the results of a single randomized trial 
where denosumab was shown to signifi cantly de-
lay time to fi rst SRE (HR, 0.82; 95% CI, 0.71–0.95; 
P<.001). No diff erence in TTP or OS was observed 
(106). Both, the bisphosphonates and denosumab, 
are associated with the occurrence of osteonecro-
sis of the jaw (ONJ). Poor baseline dental health or 
dental procedures during treatment are known 
risk factors for ONJ (107).
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